Platform Specialty Products (ESI) and Artemis Therapeutics (ATMS) Financial Analysis

Artemis Therapeutics (OTCMKTS:ATMS) and Platform Specialty Products (NYSE:ESI) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Artemis Therapeutics and Platform Specialty Products’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Artemis Therapeutics N/A -816.26% -300.00%
Platform Specialty Products -14.14% 8.48% 2.23%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Artemis Therapeutics and Platform Specialty Products, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Artemis Therapeutics 0 0 0 0 N/A
Platform Specialty Products 0 1 0 0 2.00

Platform Specialty Products has a consensus price target of $13.00, indicating a potential upside of 16.49%. Given Platform Specialty Products’ higher possible upside, analysts plainly believe Platform Specialty Products is more favorable than Artemis Therapeutics.

Valuation and Earnings

This table compares Artemis Therapeutics and Platform Specialty Products’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Artemis Therapeutics N/A N/A -$1.14 million N/A N/A
Platform Specialty Products $3.78 billion 0.85 -$296.20 million $0.76 14.68

Artemis Therapeutics has higher earnings, but lower revenue than Platform Specialty Products.

Institutional and Insider Ownership

95.0% of Platform Specialty Products shares are owned by institutional investors. 7.5% of Artemis Therapeutics shares are owned by insiders. Comparatively, 3.8% of Platform Specialty Products shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Artemis Therapeutics has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Platform Specialty Products has a beta of 2.58, meaning that its share price is 158% more volatile than the S&P 500.

Summary

Platform Specialty Products beats Artemis Therapeutics on 6 of the 9 factors compared between the two stocks.

Artemis Therapeutics Company Profile

Artemis Therapeutics Inc., a biopharmaceutical company, engages in the development of agents for the prevention and treatment of severe and life-threatening infectious diseases. The company's lead product candidate is Artemisone, an orally-administered 10-alpha-amino artemisinin derivative with antiviral and antiparasitic properties. It focuses on advancing Artemisone as an antiparasitic treatment for patients infected with Plasmodium falciparum; and as an antiviral agent to address unmet clinical needs in immunocompromised patients infected with human cytomegalovirus and other viral or infectious diseases. The company has license agreement with Hadasit Medical Research Services and Development Ltd., Hadassah Medical Organization, and Hong Kong University of Science and Technology R and D Corporation Limited for the development of Artemisone. Artemis Therapeutics Inc. was incorporated in 1997 and is based in New York, New York. Artemis Therapeutics Inc. is a subsidiary of Tonak Ltd.

Platform Specialty Products Company Profile

Platform Specialty Products Corp. engages in the provision of technology chemical products and technical services. It operates its business through the Performance Solutions and Agricultural Solutions segments. The Performance Solutions segment formulates and markets chemistry solutions that are used in production, commercial packaging and printing, electronics, and oil and gas production and drilling. The Agricultural Solutions segment is based on a solutions-oriented business model that focuses on its product improvement address an ever increasing need for higher crop yield and quality. The company was founded by Martin E. Franklin on April 23, 2013 and is headquartered in West Palm Beach, FL.

Receive News & Ratings for Artemis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artemis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply